跳至主要内容
临床试验/NCT04737213
NCT04737213Unknown2 期

An Open-label, Exploratory Study Assessing the Feasibility of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Lung Metastasis in Colorectal Cancer

Leiden University Medical Center2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2020年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
10
试验地点
2
主要终点
Ability of SGM-101 and a near-infrared camera system to detect colorectal lung metastases.

研究概览

简要总结

Near-infrared fluorescence-guided oncologic surgery (FGOS) with the use of a tumor specific tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about tumor location and extensiveness. SGM-101 already proven to be safe and valuable in colorectal cancer.

This study aims to prove feasibility for colorectal lung metastases.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent prior to any study-mandated procedure;
  • Patients aged over 18 years old;
  • All women of child bearing potential and all males must practice effective contraception during the study and be willing and able to continue contraception for at least 30 days after their last dose of study treatment.
  • Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions.
  • Diagnosed with lung metastasis of colorectal origin and scheduled for a resection.

排除标准

  • History of any anaphylactic reaction;
  • Other malignancies either currently active or diagnosed in the last 5 years, except adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma;
  • Laboratory abnormalities defined as:
  • Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the or;
  • Total bilirubin above 2 times the ULN or;
  • Serum creatinine above 1.5 times the ULN or;
  • Platelet count below 100 x 109/L or;
  • Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males);
  • Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody or patients with untreated serious infections;
  • Patients pregnant or breastfeeding (pregnancy should be ruled out by a pregnancy test within two weeks prior to administration of the conjugate);
  • Any condition that the investigator considers to be potentially jeopardizing the patient's well-being or the study objectives.
  • Previous SGM-101 use

研究组 & 干预措施

SGM-101

Experimental

Patients included with colorectal lung metastases, SGM-101 7.5-12.5mg, 3-5 days prior to surgery

干预措施: SGM-101 (Drug)

结局指标

主要结局

Ability of SGM-101 and a near-infrared camera system to detect colorectal lung metastases.

时间窗: peroperative

Intraoperative imaging of colorectal lung metastases based on the tumor-to-background ratio

次要结局

未报告次要终点

研究者

发起方
Leiden University Medical Center
申办方类型
Other
责任方
Principal Investigator
主要研究者

Alexander Vahrmeijer

Principal Investigator

Leiden University Medical Center

研究点 (2)

Loading locations...

相似试验